SCHEMBL7914722

SCHEMBL7914722

COC(=O)c1scc(C)c1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.49
PKM P14618 1/20 0.49
ATM Q13315 1/20 0.49
POLB P06746 2/20 0.48
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 1/20 0.46
HTR1A P08908 1/20 0.44
SCN1A P35498 1/20 0.44
SCN2A Q99250 1/20 0.44
SCN3A Q9NY46 1/20 0.44
KMT2A Q03164 3/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
KDM4E B2RXH2 5/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15472134 0.81 KMT2A (0.44) MAPTPKMATMPOLBKMT2A
SCHEMBL167302 0.80 MAPT (0.51) MAPTPKMATMPOLBCYP1A2
SCHEMBL3581664 0.78 MAPT (0.50) MAPTPKMATMPOLBCYP1A2
SCHEMBL1529989 0.78 MAPT (0.46) MAPTPKMATMPOLBCYP1A2
SCHEMBL25176315 0.78 GSK3B (0.39) MAPTPKMATMPOLBKMT2A
SCHEMBL2690137 0.78 POLB (0.52) PKMPOLBKMT2ATSHRKDM4E
SCHEMBL397136 0.77 MAPT (0.49) MAPTPKMATMPOLBCYP1A2
SCHEMBL163725 0.77 KDM4E (0.57) MAPTPKMATMPOLBCYP1A2
SCHEMBL2987502 0.77 MAPT (0.49) MAPTPKMATMPOLBCYP1A2
SCHEMBL17834830 0.77 MAPT (0.53) MAPTPKMATMPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025097104-A1 THIENYL COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER PGI DRUG DISCOVERY LLC (US) 2025-05-08 WO disclosed
CN-118852196-A CYP11B2 inhibitor compound, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2024-10-29 CN disclosed
CN-107074873-B 7- (morpholinyl) -2- (N-piperazinyl) methylthioeno [2, 3-c ] pyridine derivatives as anticancer agents 纳科法尔马有限公司 2022-01-07 CN disclosed
EP-3230289-B1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LTD (IN) 2019-08-14 EP disclosed
EP-3230289-B1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LTD (IN) 2019-08-14 EP disclosed
US-10106554-B2 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs NATCO PHARMA LIMITED (IN) 2018-10-23 US disclosed
US-20170320891-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LIMITED (IN) 2017-11-09 US disclosed
US-20170320891-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LIMITED (IN) 2017-11-09 US disclosed
US-20170320891-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS NATCO PHARMA LIMITED (IN) 2017-11-09 US disclosed
EP-3230289-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C]PYRIDINE DERIVATIVES AS ANTICANCER DRUGS Natco Pharma Limited (IN) 2017-10-18 EP disclosed
US-20140155433-A1 BIARYL DERIVATIVES AS NACHR MODULATORS LUPIN LIMITED (IN) 2014-06-05 US disclosed
EP-2729455-A1 BIARYL DERIVATIVES AS NACHR MODULATORS Lupin Limited (IN) 2014-05-14 EP disclosed
EP-2678327-A1 HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS Lupin Limited (IN) 2014-01-01 EP disclosed
US-20130331387-A1 HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS LUPIN LIMITED (IN) 2013-12-12 US disclosed
WO-2013005153-A1 BIARYL DERIVATIVES AS NACHR MODULATORS LUPIN LIMITED (IN) 2013-01-10 WO disclosed
WO-2012114285-A9 HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS LUPIN LIMITED (IN) 2012-10-18 WO disclosed
WO-2012114285-A9 HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS LUPIN LIMITED (IN) 2012-10-18 WO disclosed
WO-2012114285-A1 HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS LUPIN LIMITED (IN) 2012-08-30 WO disclosed
US-6200931-B1 FOR CONTROLLING WEEDS BAYER AKTIENGESELLSCHAFT (DE) 2001-03-13 US disclosed
CN-1234034-A 5,6-dihydro-[1,4,2]-dioxazin-subsd. (hetero) aryl-(oxy-, imino-, alkyl)-sulphonylamino (thio) carbonyl-heterocyclyl derivatives, their prepn. and use as herbicides BAYER AG (DE) 1999-11-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106554-B2 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs PRMT7, CDK7, CASP7 MAPT 1629/4885PKM 2229/4885ATM 1548/4885
US-20170320891-A1 7-(MORPHOLINYL)-2-(N-PIPERAZINYL) METHYL THIENO [2, 3-C] PYRIDINE DERIVATIVES AS ANTICANCER DRUGS PRMT7, CDK7, CASP7 MAPT 1629/4885PKM 2229/4885ATM 1548/4885
US-20140155433-A1 BIARYL DERIVATIVES AS NACHR MODULATORS CHRM2, CHRM1, CHRM5 MAPT 330/4885PKM 2682/4885ATM 1857/4885
US-20130331387-A1 HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS CHRNA7, CHRM1, CHRM2 MAPT 413/4885PKM 2785/4885ATM 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.